… Afatinib had a superior tendency in terms of CNS-PFS, and cumulative incidence of CNS
failure compared with gefitinib or erlotinib. However, our study, as a retrospective study, has …

… included in this study retrospectively. All patients were administered with gefitinib plus anlotinib
… Citation14 Therefore, we noticed that bevacizumab plus erlotinib combination therapy …

… trial validated the efficacy of osimertinib to platinum-based combination chemotherapy plus
pemetrexed, in advanced NSCLC patients who developed resistance to erlotinib or gefitinib …

… in a phase III trial (FLAURA),12 osimertinib showed a longer PFS than gefitinib or erlotinib
when … Therefore, we retrospectively evaluated patient characteristics, treatment status, and the …

… Herein, we present the results of our retrospective analysis data to evaluate the survival
benefit of first-line EGFR-TKI therapy, as compared to that of cytotoxic chemotherapy or best …

… confirmed by another recent retrospective study based on a … , one phase III trial evaluated
the adjuvant use of gefitinib in … Another randomized, phase II, open-label, multicenter study (…

… effectiveness and safety of afatinib, gefitinib, and erlotinib for elderly patients with epidermal
… , this study aimed to describe the effectiveness and safety of afatinib, gefitinib, and erlotinib …

… were included in this retrospective multicentric data analysis (… in this study actually had
poorer outcomes with gefitinib (hazard … is more cost effective than erlotinib, further information is …

… III clinical trial of a third-generation novel agent ASP8273 versus erlotinib or gefitinib in
patients … A multicenter study (47) showed that 14.8% of stage III patients underwent surgery. In …

… prospective and retrospective studies evaluating the efficacy and safety of gefitinib, erlotinib,
and … In fact, the NEJ003 study is the first to report the efficacy and safety of gefitinib in elderly …